- Home
- DXC vs VCEL Comparison
DXC vs VCEL Comparison
Compare DXC & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXC | VCEL |
|---|---|---|
| Founded | 1959 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | DXC | VCEL |
|---|---|---|
| Price | $15.11 | $37.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $15.33 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 2.2M | 605.5K |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1492.90 | 236.54 |
| EPS | ★ 2.03 | 0.25 |
| Revenue | ★ $12,714,000,000.00 | $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | N/A | $18.55 |
| P/E Ratio | ★ $7.44 | $152.30 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $11.82 | $29.24 |
| 52 Week High | $23.75 | $63.00 |
Technical Indicators
Market Signals| Indicator | DXC | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 62.15 | 51.30 |
| Support Level | $15.06 | $35.53 |
| Resistance Level | $15.51 | $38.09 |
| Average True Range (ATR) | 0.41 | 1.36 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 67.60 | 70.84 |
Price Performance
Historical ComparisonAbout DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.